Market Overview

Leerink Swann Reiterates Outperform On Rigel Pharma As Shares Plunge 12+% On Missed R343 Trial Endpoints

Related RIGL
Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings
Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

Shares of Rigel Pharma (NASDAQ: RIGL) have traded down around 12-13 percent throughout Monday morning's trading session following some concerning data from a trial of its R343. Rigel shares have bounced sharply from the pre-market low under $2.50.

Analyst Marko Kozul at Leerink Swann, a firm which specializes in the Pharma group, said he was surprised by the failure of the R343 trial to miss the primary and secondary endpoints.

Although the analyst was caught off guard, he cited low expectations for the remaining three catalysts over the near term for his reiterated Outperform rating. Kozul adjusted his price target on Rigel Pharma lower from $7 previously to $5.

With Rigel shares down to around $3.18 at last check, Kozul's new, lowered price target still represents potential upside of nearly 60 percent.

Latest Ratings for RIGL

May 2018BMO CapitalMaintainsOutperformOutperform
May 2018H.C. WainwrightMaintainsBuyBuy
Apr 2018BMO CapitalMaintainsOutperformOutperform

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Reiteration FDA Analyst Ratings Movers


Related Articles (RIGL)

View Comments and Join the Discussion!